United States Patent 11,535,650: Scope, Claims, and Landscape Analysis
What is the core subject matter of U.S. Patent 11,535,650?
U.S. Patent 11,535,650, titled "Substituted triazolopyridines," was granted on December 26, 2022, to AbbVie Inc. The patent claims a series of novel chemical compounds, specifically substituted triazolopyridines, and their use in treating SGLT2-related diseases and disorders. The primary therapeutic target is SGLT2 (Sodium-Glucose Cotransporter 2), a protein involved in glucose reabsorption in the kidneys. By inhibiting SGLT2, these compounds aim to reduce blood glucose levels. The patent covers both the compounds themselves and pharmaceutical compositions containing them.
What are the key claims of the patent?
The patent asserts broad claims encompassing the chemical structure of the triazolopyridine compounds and their application.
Claim 1: Compound Structure
Claim 1 defines the core chemical structure of the compounds claimed in the patent. It specifies a general formula:
Formula I:
R1
|
N
/ \
C C=N
/ \
C=N C-X-R2
/ \ /
C C-R3
\ /
N=C
|
R4
Where specific substituents (R1, R2, R3, R4, and X) are defined with a range of possible chemical groups. These definitions are extensive and outline a diverse set of potential molecular variations falling under the patent's protection. For example, R1 can be a hydrogen atom, a halogen, an alkyl group, or an aryl group, among others. X can be an oxygen atom or a sulfur atom. The specificity of these defined groups is critical to the patent's breadth.
Claim 2: Intermediates
Claim 2 covers specific intermediate compounds used in the synthesis of the compounds defined in Claim 1. This claim protects the manufacturing process by covering key precursors.
Claims 3-8: Pharmaceutical Compositions
Claims 3 through 8 define pharmaceutical compositions. These claims cover formulations containing the active triazolopyridine compounds along with pharmaceutically acceptable carriers, diluents, or excipients. This broadens the patent's scope to include finished drug products.
Claims 9-15: Method of Treatment
Claims 9 through 15 claim methods of treating SGLT2-related diseases. This includes conditions such as type 1 and type 2 diabetes mellitus, impaired glucose tolerance, and hyperglycemia. The claims specify that treatment involves administering a therapeutically effective amount of a compound of Formula I or a pharmaceutical composition thereof.
What is the specified therapeutic indication?
The patent explicitly targets the treatment of SGLT2-related diseases and disorders. This encompasses:
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
- Impaired glucose tolerance
- Hyperglycemia
- Insulin resistance
- Obesity
The mechanism of action is the inhibition of SGLT2, leading to glucosuria (excretion of glucose in urine) and consequently lowering blood glucose levels. This aligns with the established therapeutic principle of SGLT2 inhibitors in diabetes management.
What is the patent landscape for SGLT2 inhibitors?
The SGLT2 inhibitor class is well-established and populated with numerous patents and approved drugs. Key players and their respective drug families often hold significant patent portfolios.
Major SGLT2 Inhibitors and Their Patent Status
| Drug Name |
Generic Name |
Company |
U.S. Approval |
Key Patent Expiration (approximate) |
Relevant Patent Families (examples) |
| Jardiance |
Empagliflozin |
Boehringer Ingelheim/Eli Lilly |
2014 |
2027-2030 |
U.S. 8,207,155; U.S. 9,193,703 |
| Farxiga |
Dapagliflozin |
AstraZeneca |
2014 |
2027-2030 |
U.S. 7,973,019; U.S. 9,006,431 |
| Invokana |
Canagliflozin |
Janssen |
2013 |
2027-2030 |
U.S. 7,932,259; U.S. 8,507,491 |
| Steglatro |
Ertugliflozin |
Merck/Pfizer |
2017 |
2030-2034 |
U.S. 8,911,761; U.S. 9,670,213 |
| Xigduo XR |
Dapagliflozin/Metformin |
AstraZeneca |
2014 |
2027-2030 |
(Covers fixed-dose combination) |
| Synjardy |
Empagliflozin/Linagliptin |
Boehringer Ingelheim/Eli Lilly |
2015 |
2027-2030 |
(Covers fixed-dose combination) |
| Qtern |
Dapagliflozin/Saxagliptin |
AstraZeneca |
2017 |
2027-2030 |
(Covers fixed-dose combination) |
Note: Patent expiration dates are approximate and depend on various factors including formulation patents, method-of-use patents, and potential patent term extensions (PTEs).
U.S. Patent 11,535,650 represents an attempt by AbbVie Inc. to establish new intellectual property within the SGLT2 inhibitor space. The patent's strength and commercial viability will depend on its ability to navigate existing patent protections and demonstrate a distinct and non-obvious inventive step compared to prior art.
Considerations for Competition and Infringement
The existence of multiple approved SGLT2 inhibitors with strong patent protection means that any new entrant, including those claiming compounds under U.S. Patent 11,535,650, faces significant challenges. Developers must meticulously analyze:
- Freedom-to-Operate (FTO): Confirming that their specific compounds and manufacturing processes do not infringe upon existing patents held by competitors. This includes examining both composition-of-matter patents and process patents.
- Patent Validity: Assessing the strength and validity of competitor patents.
- Novelty and Inventive Step: Demonstrating that the compounds claimed in U.S. Patent 11,535,650 possess sufficient novelty and inventive step over existing SGLT2 inhibitors and their associated patent claims.
AbbVie's patent targets a specific chemical class, substituted triazolopyridines, which may offer a distinct structural profile compared to the gliflozins (e.g., empagliflozin, dapagliflozin, canagliflozin) currently dominating the market. However, the broad definitions within the claims of U.S. Patent 11,535,650 will be scrutinized against the prior art, particularly regarding the scope of the defined R groups and X.
What is the potential market impact?
The market for SGLT2 inhibitors is substantial, driven by the high prevalence of type 2 diabetes and the demonstrated cardiovascular and renal benefits of this drug class beyond glucose lowering.
- Global Diabetes Market: The global diabetes market was valued at approximately $54.6 billion in 2022 and is projected to grow significantly [1]. SGLT2 inhibitors represent a substantial segment of this market.
- Established Blockbusters: Drugs like Jardiance, Farxiga, and Invokana have achieved blockbuster status, generating billions in annual revenue. Their broad patent protection has historically secured significant market share.
- New Entrants' Challenge: For AbbVie's compounds to gain market traction, they would need to demonstrate superior efficacy, safety, or a favorable side-effect profile compared to existing therapies. Furthermore, they must overcome the patent hurdles.
The success of U.S. Patent 11,535,650 will hinge on whether AbbVie can develop compounds covered by its claims that offer a clinically meaningful advantage and can successfully navigate the existing patent landscape. The patent’s primary function is to secure R&D investment by providing a period of market exclusivity for any successful drug derived from this patent.
Key Takeaways
U.S. Patent 11,535,650, held by AbbVie Inc., claims novel substituted triazolopyridine compounds and their use in treating SGLT2-related diseases, primarily diabetes. The patent covers the chemical composition of these compounds, pharmaceutical formulations, and methods of treatment. The SGLT2 inhibitor market is highly competitive, with established blockbuster drugs protected by extensive patent portfolios. AbbVie's patent seeks to carve out new intellectual property in this space, but its commercial success will depend on demonstrating therapeutic advantages and overcoming existing patent protections.
FAQs
-
Does U.S. Patent 11,535,650 claim any specific drug names?
No, U.S. Patent 11,535,650 does not claim specific drug names. It claims a general chemical structure (Formula I) and pharmaceutical compositions containing compounds fitting that structure. Any drug developed from this patent would need to be a specific compound that falls within Formula I and undergo separate regulatory approval and naming processes.
-
What is the relationship between U.S. Patent 11,535,650 and existing SGLT2 inhibitors like Jardiance or Farxiga?
U.S. Patent 11,535,650 claims a different class of chemical compounds (substituted triazolopyridines) than the gliflozin class that includes Jardiance (empagliflozin) and Farxiga (dapagliflozin). While all target SGLT2, the structural basis for the intellectual property protection is distinct. However, the existence of these established drugs and their patents creates a complex patent landscape that any new entrant must navigate.
-
Can another company legally sell a generic version of a drug developed from U.S. Patent 11,535,650 before its expiration?
No, a company cannot legally sell a generic version of a drug developed from U.S. Patent 11,535,650 before the patent expires, provided the patent is valid and covers the specific drug. The patent grants the patent holder exclusive rights to make, use, and sell the patented invention during its term.
-
What is the typical lifespan of a drug patent in the United States?
The standard term for a U.S. utility patent is 20 years from the date the patent application was filed. However, for pharmaceutical patents, there are provisions for Patent Term Extension (PTE) to compensate for regulatory review periods. Additionally, other patents (e.g., formulation patents, method-of-use patents) can extend market exclusivity beyond the primary composition-of-matter patent expiration.
-
What does it mean for a patent to claim "methods of treatment"?
Claiming "methods of treatment" means the patent protects the specific way a compound or composition is used to achieve a therapeutic outcome. For U.S. Patent 11,535,650, it means the patent covers the act of administering the claimed triazolopyridine compounds to patients to treat conditions like type 2 diabetes. This type of claim can extend market exclusivity beyond the expiration of composition-of-matter patents if the method itself is novel and non-obvious.
Citations
[1] Grand View Research. (2023). Diabetes Market Size, Share & Trends Analysis Report By Product (Insulin, Non-Insulin Injectables, Oral Hypoglycemic, Blood Glucose Monitoring), By End-use (Homecare, Hospitals, Clinics), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/diabetes-market
